Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real
Medicina Clínica · 2026-08 · 166 (8) · 107448
DOI: 10.1016/j.medcli.2026.107448 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Medicina Clínica, 2026-08. Verfasst von Ester Zamarrón de Lucas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España. Electronic address: Ester.zam…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Benzodioxoles, Quinolones, Indoles. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
INTRODUCTION CFTR modulators have significantly changed the prognosis of cystic fibrosis (CF), although data on their long-term clinical and microbiological impact in adults in real-world practice remain limited. OBJECTIVE To analyze the clinical, functional, and microbiological outcomes at 36 months in adults with CF treated with elexacaftor/tezacaftor/ivacaftor (ETI). METHODS A longitudinal observational study was conducted in adults with CF. Lung function, number of exacerbations, weight, and sputum cultures were assessed at baseline and at 12, 24, and 36 months after initiation of ETI. RESULTS A total of 55 patients were included (43.6% female; mean age 32±13 years). FEV1 improved at 12 months and remained stable at 36 months. Exacerbations decreased, and weight increased progressively. The proportion of patients with potentially pathogenic microorganisms decreased from 93.1% at baseline to 36.2% at 36 months. Patients without microbiological isolation showed better lung function and fewer exacerbations. CONCLUSIONS In real-world clinical practice, ETI is associated with improvements in lung function, weight, and exacerbations, as well as a reduction in the isolation of potentially pathogenic microorganisms in sputum at 36 months.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España. Electronic address: Ester.zamarron@gmail.com.
- Servicio de Neumología, Hospital Universitario La Paz. IdiPAZ. Universidad Autónoma de Madrid. CIBERER, Madrid, España.
Zitieren
APA
Zamarrón de Lucas, E., Crespo Catalán, C., Romero Campos, B., Sanz Sanjosé, B., Longás Ouzzine, M., Aponte Guevara, C. S., Álvarez-Sala Walther, R., & Prados Sánchez, M. C. (2026). Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real. Medicina Clínica, 166(8), 107448. https://doi.org/10.1016/j.medcli.2026.107448
Vancouver
Zamarrón de Lucas E, Crespo Catalán C, Romero Campos B, Sanz Sanjosé B, Longás Ouzzine M, Aponte Guevara CS, et al. Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real. Medicina Clínica. 2026;166(8):107448. doi:10.1016/j.medcli.2026.107448
BibTeX
@article{ZamarrndeLucas2026,
author = {Zamarrón de Lucas, Ester and Crespo Catalán, Clara and Romero Campos, Belén and Sanz Sanjosé, Belén and Longás Ouzzine, María and Aponte Guevara, Cindy Stephania and Álvarez-Sala Walther, Rodolfo and Prados Sánchez, María Concepción},
title = {Elexacaftor/tezacaftor/ivacaftor en adultos con fibrosis quística: resultados a 3 años en práctica clínica real},
journal = {Medicina Clínica},
year = {2026},
volume = {166},
number = {8},
pages = {107448},
doi = {10.1016/j.medcli.2026.107448}
}
EUVIMED